WO2001051004A3 - Agent anticancereux contenant un compose naphtoquinone - Google Patents

Agent anticancereux contenant un compose naphtoquinone Download PDF

Info

Publication number
WO2001051004A3
WO2001051004A3 PCT/KR2001/000026 KR0100026W WO0151004A3 WO 2001051004 A3 WO2001051004 A3 WO 2001051004A3 KR 0100026 W KR0100026 W KR 0100026W WO 0151004 A3 WO0151004 A3 WO 0151004A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbons
formula
containing naphthoquinone
agent containing
alkene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2001/000026
Other languages
English (en)
Other versions
WO2001051004A2 (fr
Inventor
Hee-Yong Han
Young-Bum Kim
Jeong-Soo Kim
Ho-Jin Park
Moon-Jong Noh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kolon Industries Inc
Original Assignee
Kolon Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kolon Industries Inc filed Critical Kolon Industries Inc
Publication of WO2001051004A2 publication Critical patent/WO2001051004A2/fr
Publication of WO2001051004A3 publication Critical patent/WO2001051004A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L"invention concerne un médicament anticancéreux contenant un composé naphtoquinone, et plus particulièrement, un médicament anticancéreux contenant des composés naphtoquinone représentés par les formules (1), dans laquelle R1 et R2 sont identiques ou différents et sont chacun choisis dans le groupe constitué par hydrogène, hydroxy, alcoxy C1-C10, alkyle C1-C10, ester C1-C10 et alcène C1-C10; et (2), dans laquelle R1 et R2 sont identiques ou différents et sont chacun choisis dans le groupe constitué par hydrogène, hydroxy, amine primaire, amine, secondaire, amine tertiaire, acide carboxylique, alcoxy C1-C10, alkyle C1-C10, ester C1-C10 et alcène C1-C10; et R3 et R5 sont identiques ou différents et sont chacun choisis dans le groupe constitué par hydrogène, hydroxy, alcoxy C1-C10, alkyle C1-C10, ester C1-C10 et alcène C1-C10. Ce médicament anticancéreux présente une faible toxicité et une activité anticancéreuse remarquable.
PCT/KR2001/000026 2000-01-10 2001-01-09 Agent anticancereux contenant un compose naphtoquinone Ceased WO2001051004A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20000000954 2000-01-10
KR2000/954 2000-01-10
KR10-2000-0085805A KR100406736B1 (ko) 2000-01-10 2000-12-29 나프토퀴논계 화합물을 포함하는 항암제
KR2000/85805 2000-12-29

Publications (2)

Publication Number Publication Date
WO2001051004A2 WO2001051004A2 (fr) 2001-07-19
WO2001051004A3 true WO2001051004A3 (fr) 2002-01-17

Family

ID=26636690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2001/000026 Ceased WO2001051004A2 (fr) 2000-01-10 2001-01-09 Agent anticancereux contenant un compose naphtoquinone

Country Status (2)

Country Link
KR (1) KR100406736B1 (fr)
WO (1) WO2001051004A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100406736B1 (ko) * 2000-01-10 2003-11-21 주식회사 코오롱 나프토퀴논계 화합물을 포함하는 항암제
KR100455458B1 (ko) * 2001-10-18 2004-11-08 (주)바이오니아 1,2-나프토퀴논유도체 및 약학적으로 허용되는 이들의염과 그 제조방법
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
CN1318414C (zh) * 2004-12-30 2007-05-30 中山大学 含邻萘醌结构的化合物及其应用
CN102716116B (zh) * 2010-12-07 2013-11-06 中山大学 含邻醌结构的化合物在制备抗肿瘤药物中的应用
CN102125545B (zh) * 2010-12-07 2013-11-06 中山大学 含邻醌结构的化合物在制备抗肿瘤药物中的应用
CN103183668A (zh) * 2013-02-19 2013-07-03 中山大学 一种天然产物曼宋酮e的衍生物及其制备与应用
CN104744421B (zh) * 2015-01-08 2017-06-06 中山大学 一种Mansonone F的衍生物及其制备方法和应用
KR101990054B1 (ko) * 2017-04-25 2019-06-17 대구대학교 산학협력단 로손을 유효성분으로 포함하는 항암 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980067139A (ko) * 1997-01-31 1998-10-15 서영거 만소논에프를 주성분으로 하는 항균제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63270673A (ja) * 1987-04-30 1988-11-08 Nobuo Ikegawa 制癌剤とその製造方法
KR100406736B1 (ko) * 2000-01-10 2003-11-21 주식회사 코오롱 나프토퀴논계 화합물을 포함하는 항암제
KR100462844B1 (ko) * 2000-12-06 2004-12-20 한국생명공학연구원 느릅나무과로부터 분리한 신규한 화합물 및 그 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980067139A (ko) * 1997-01-31 1998-10-15 서영거 만소논에프를 주성분으로 하는 항균제

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN C.M. ET AL.: "Constituents of formosan antitumor folk medicine. Part 3. A mansonone from helicteres angustifolia", PHYTOCHEMISTRY, vol. 29, no. 3, 1990, pages 980 - 982 *
FERNANDEZ ET AL.: "Redox cycling of o-naphtoquinones in trypanosomatids. Superoxide and hydrogen peroxide production", BIOCHEM. PHARMACOL., vol. 52, no. 12, 1996, pages 1875 - 1882, XP008047536, DOI: doi:10.1016/S0006-2952(96)00601-6 *
INBARAJ ET AL.: "Cytotoxicity and superoxide anion generation by some naturally occurring quinones", FREE RADICAL BIOL. MED., vol. 26, no. 9/10, 1999, pages 1072 - 1078 *
KIM J.P. ET AL.: "Isolation and identification of sesquiterpene o-naphtoquinones, mansonones E,F and H, from the root bark of Ulmus davidiana planch", HAN'GUK NONGHWA HAKHOECHI, vol. 39, no. 1, 1996, pages 89 - 94, XP053020844 *

Also Published As

Publication number Publication date
KR20010070381A (ko) 2001-07-25
KR100406736B1 (ko) 2003-11-21
WO2001051004A2 (fr) 2001-07-19

Similar Documents

Publication Publication Date Title
JO2654B1 (en) Multiple aryl caroxa amides are useful as lipid - lowering agents
AU2001293826A1 (en) Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
SG151249A1 (en) 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
BG103485A (en) Ketobanzamides as calpain inhibitors
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
WO2002024686A3 (fr) Derives de la quinoleine et de la quinazoline 6-heterocyclylmethyle inhibiteurs de la farnesyle transferase
EP1340755A4 (fr) Agents de traitement des infections a helicobacter
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
WO2002000638A3 (fr) Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant
WO2001051004A3 (fr) Agent anticancereux contenant un compose naphtoquinone
NZ513594A (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
WO2002014313A3 (fr) Nouveaux inhibiteurs de beta-amyloide, leurs procedes de production et leur utilisation comme medicaments
MY128392A (en) 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(2-FURANYLCARBOXYL)OXY]-11ß-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
ATE240331T1 (de) Azatricyclo(3.3.1.1)decanderivate und diese enthaltende phrmazeutische zubereitungen
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
WO2003024913A1 (fr) Derives d'acides benzoiques substitues possedant une activite d'inhibition de nf-kb
WO2003080631A3 (fr) Inhibiteurs de plasma carboxypeptidase b
UA93529C2 (ru) Соли и смеси 9-оксоакридин-10-уксусной кислоты c 1-алкиламино-1-дезоксиполиолами
DE60119383D1 (de) Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
DE69827614D1 (de) Chinoxalindionen
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
AP2001002314A0 (en) Substituted benzolactam compounds.
EP1321141A4 (fr) Inhibiteurs de la production de parathormone contenant des derives de vitamine d3
AU2002217356A1 (en) Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient
AU2002214056A1 (en) Farnesyl transferase inhibiting benzoheterocyclic derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CN JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP